Delcath Systems Inc.

3.92+0.0400+1.03%Vol 11.85K1Y Perf -64.86%
Jun 24th, 2022 16:00 DELAYED
BID3.42 ASK4.25
Open3.63 Previous Close3.88
Pre-Market- After-Market-
 - -  - -%
Target Price
20.33 
Analyst Rating
Strong Buy 1.00
Potential %
418.62 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
     33.34
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★+     41.78
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
4.30 
Earnings Rating
Market Cap30.99M 
Earnings Date
9th Aug 2022
Alpha-0.07 Standard Deviation0.22
Beta1.18 

Today's Price Range

3.633.98

52W Range

3.4913.50

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
8.29%
1 Month
-12.50%
3 Months
-36.67%
6 Months
-53.61%
1 Year
-64.86%
3 Years
-95.33%
5 Years
-100.00%
10 Years
-100.00%

TickerPriceChg.Chg.%
DCTH3.920.04001.03
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Financial StrengthValueIndustryS&P 500US Markets
1.90
2.90
0.72
3.13
-14.10
Leverage Ratio 2.70
ProfitabilityValueIndustryS&P 500US Markets
52.50
-714.10
-710.20
-901.80
-
RevenueValueIndustryS&P 500US Markets
3.54M
0.45
11.93
0.95
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.84-1.00-19.05
Q04 2021-0.93-0.6925.81
Q03 2021-0.91-0.94-3.30
Q02 2021-0.98-0.962.04
Q01 2021-0.89-1.04-16.85
Q04 2020-0.82-0.6125.61
Q03 2020-1.15-1.16-0.87
Q02 2020-1.38-1.90-37.68
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date9th Aug 2022
Estimated EPS Next Report-0.88
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume11.85K
Shares Outstanding7.91K
Shares Float7.02M
Trades Count91
Dollar Volume46.10K
Avg. Volume26.86K
Avg. Weekly Volume21.73K
Avg. Monthly Volume31.72K
Avg. Quarterly Volume27.11K

Delcath Systems Inc. (NASDAQ: DCTH) stock closed at 3.92 per share at the end of the most recent trading day (a 1.03% change compared to the prior day closing price) with a volume of 11.85K shares and market capitalization of 30.99M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 36 people. Delcath Systems Inc. CEO is Gerard J. Michel.

The one-year performance of Delcath Systems Inc. stock is -64.86%, while year-to-date (YTD) performance is -49.42%. DCTH stock has a five-year performance of -100%. Its 52-week range is between 3.49 and 13.5, which gives DCTH stock a 52-week price range ratio of 4.30%

Delcath Systems Inc. currently has a PE ratio of -1.00, a price-to-book (PB) ratio of 5.48, a price-to-sale (PS) ratio of 8.08, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -93.74%, a ROC of -114.10% and a ROE of -224.79%. The company’s profit margin is -%, its EBITDA margin is -710.20%, and its revenue ttm is $3.54 Million , which makes it $0.45 revenue per share.

Of the last four earnings reports from Delcath Systems Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.88 for the next earnings report. Delcath Systems Inc.’s next earnings report date is 09th Aug 2022.

The consensus rating of Wall Street analysts for Delcath Systems Inc. is Strong Buy (1), with a target price of $20.33, which is +418.62% compared to the current price. The earnings rating for Delcath Systems Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Delcath Systems Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Delcath Systems Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 47.62, ATR14 : 0.29, CCI20 : -62.27, Chaikin Money Flow : -0.07, MACD : -0.33, Money Flow Index : 33.29, ROC : -4.85, RSI : 35.34, STOCH (14,3) : 40.57, STOCH RSI : 1.00, UO : 40.22, Williams %R : -59.43), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Delcath Systems Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (100.00 %)
2 (100.00 %)
2 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Delcath Systems Inc.

Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product candidate, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System, or Melphalan/HDS, is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.

CEO: Gerard J. Michel

Telephone: +1 212 489-2100

Address: 1633 Broadway, New York 10019, NY, US

Number of employees: 36

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

54%46%

TipRanks News for DCTH

Tue, 29 Mar 2022 10:15 GMT Analysts Top Healthcare Picks: Delcath Systems (DCTH), CASI Pharmaceuticals (CASI)

- TipRanks. All rights reserved.

Fri, 25 Mar 2022 15:48 GMT Delcath Systems (DCTH) Gets a Buy Rating from BTIG

- TipRanks. All rights reserved.

News

Stocktwits